ReviewJournal of the Egyptian National Cancer Institute2025
Iron oxide nanoparticles in leukemia: design, diagnostic applications, and therapeutic strategies.
Review in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Novel Achievements in Oncological Metabolic Radio-Therapy: Isotope Technologies, Targeted Theranostics, Translational Oncology Research.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia, a heterogeneous group of hematologic malignancies, poses significant challenges in terms of early diagnosis and effective treatment. Recent advancements in nanotechnology have paved the way for innovative approaches in leukemia management, with a particular focus on IONPs. This review paper explores the diverse designs of IONPs and their multifaceted applications in the diagnosis and treatment of leukemia. Focused discussions on the synergistic combination of IONPs with conventional chemotherapy, targeted drug delivery, and hyperthermia-based approaches provide insights into the evolving landscape of IONP-mediated leukemia therapy. The role of IONPs in overcoming drug resistance mechanisms and minimizing off-target effects is critically evaluated. The later review section provides an overview of the unique physical, chemical, and magnetic properties of IONPs, emphasizing their biocompatibility, tunable magnetic properties, and surface functionalization capabilities. The review finally addresses the challenges and prospects associated with the clinical translation of IONP-based diagnostic approaches. By addressing the challenges and opportunities in this burgeoning field, this paper aims to guide future research endeavors toward the development of effective and personalized nanotherapeutics for leukemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.